Supriya Lifescience Ltd

Relaxo Footwears Ltd, Wockhardt Ltd, Netweb Technologies India Ltd and Ashapura Minechem Ltd are among the other gainers in the BSE's 'A' group today, 29 May 2026.Supriya Lifescience Ltd spiked 18.53% to Rs 956.85 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 2.02 lakh shares were traded on the counter so far as against the average daily volumes of 14618 shares in the past one month. Relaxo Footwears Ltd soared 16.50% to Rs 351.65. The stock was the second biggest gainer in 'A' group. On the BSE, 10.76 lakh shares were traded on the counter so far as against the average daily volumes of 11888 shares in the past one month. Wockhardt Ltd surged 14.52% to Rs 2028.95. The stock was the third biggest gainer in 'A' group. On the BSE, 4.01 lakh shares were traded on the counter so far as against the average daily volumes of 2.6 lakh shares in the past one month. Netweb Technologies India Ltd gained 12.32% to Rs 4571.5. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.73 lakh shares were traded on the counter so far as against the average daily volumes of 1.17 lakh shares in the past one month. Ashapura Minechem Ltd jumped 10.90% to Rs 726. The stock was the fifth biggest gainer in 'A' group. On the BSE, 1.88 lakh shares were traded on the counter so far as against the average daily volumes of 48694 shares in the past one month.

The company's consolidated net profit rose 47.4% YoY and 49.4% QoQ to Rs 74.23 crore in Q4 FY26. Revenue from operations jumped 50.2% YoY and 34% QoQ to Rs 276.53 crore in the March 2026 quarter. EBITDA stood at Rs 97.62 crore in Q4 FY26, up 44.4% vs Q4 FY25 and 35.4% vs Q3 FY26. EBITDA margin came in at 35.3% compared with 36.7% in Q4 FY25 and 34.9% in Q3 FY26. PBT stood at Rs 92.13 crore in Q4 FY26, up 37.7% vs Q3 and 43.8% vs Q4 FY25. On the cost front, cost of goods sold surged 92.1% YoY to Rs 105.33 crore. Employee benefit expenses increased 18.3% to Rs 24.82 crore, while other expenses rose 19.8% to Rs 48.77 crore. Finance costs stood at Rs 0.47 crore, up 12.1% YoY, and depreciation and amortisation expenses increased 39.8% to Rs 8.50 crore. For FY26, revenue from operations rose 18.9% YoY to Rs 827.87 crore from Rs 696.48 crore in FY25. Profit after tax increased 11.3% to Rs 209.12 crore, while EBITDA grew 12.8% to Rs 294.05 crore. EBITDA margin stood at 35.5% compared with 37.4% in FY25. The anesthetic segment remained the largest growth driver during FY26, contributing 54% of total revenue against 49% in FY25. The vitamins segment also strengthened its contribution to 12% from 11% a year ago. Europe continued to be the company's largest market, accounting for 40% of FY26 revenue and 44% of Q4 FY26 revenue, followed by Asia at 33% and LATAM at 20%. Export sales remained strong at around 82% of FY26 revenue. During the year, Supriya Lifescience commercialised its Liquid Anesthetic product and reported encouraging traction from newly launched products in the cardiovascular and ADHD segments. Capacity utilisation improved to 74% in FY26 from 70% in FY25, supported by the ramp-up of Module E at its Lote facility. The company also strengthened its expansion roadmap through strategic land acquisitions near its existing facilities and at Isambe, Patalganga. Meanwhile, the Ambernath formulation facility commissioned five finished dosage manufacturing lines and continued validation and dossier submission activities for regulated markets. Commenting on the performance, executive chairman and whole-time director Dr. Satish Wagh said the company benefited from healthy demand across therapeutic segments, expansion in global markets and contribution from newly launched products. He added that investments in manufacturing, R&D and backward integration continue to strengthen the foundation for long-term growth. Supriya Lifescience is a Mumbai-based manufacturer of active pharmaceutical ingredients with a presence in more than 120 countries. The company serves therapeutic segments including antihistamines, anti-allergics, vitamins, anaesthetics and anti-asthmatics. Powered by Capital Market - Live

Supriya Lifesciences announced that the Board of Directors of the Company at its meeting held on 27 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Net profit of Supriya Lifescience rose 47.34% to Rs 74.23 crore in the quarter ended March 2026 as against Rs 50.38 crore during the previous quarter ended March 2025. Sales rose 50.20% to Rs 276.53 crore in the quarter ended March 2026 as against Rs 184.11 crore during the previous quarter ended March 2025. For the full year,net profit rose 11.26% to Rs 209.12 crore in the year ended March 2026 as against Rs 187.96 crore during the previous year ended March 2025. Sales rose 18.86% to Rs 827.88 crore in the year ended March 2026 as against Rs 696.49 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales276.53184.11 50 827.88696.49 19 OPM %35.3036.71 -35.5237.44 - PBDT100.6370.14 43 303.65268.93 13 PBT92.1364.06 44 275.24248.49 11 NP74.2350.38 47 209.12187.96 11 Powered by Capital Market - Live

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 27 May 2026.

Supriya Lifescience announced that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the Company's manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026. The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating 'Voluntary Action Indicated (VAI)', signifying a successful completion of the inspection.

The USFDA had conducted an inspection of the facility from 2 February 2026 to 6 February 2026. Following the inspection, the regulator issued a Form 483 with one minor observation and classifed the facility under voluntary action indicated status, which the company said has been adequately addressed. The company said that it remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities. Supriya Lifesciences is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals.The company's primary focus is to build intermediaries and API for innovators and generic firms. It also exclusively collaborates with partners in the capacity of CMOs. The company's standalone net profit increased 6.18% to Rs 49.67 crore on 11.2% jump in revenue from operations to Rs 206.44 crore in Q4 FY26 over Q3 FY25.

Net profit of Supriya Lifescience rose 6.20% to Rs 49.68 crore in the quarter ended December 2025 as against Rs 46.78 crore during the previous quarter ended December 2024. Sales rose 11.20% to Rs 206.44 crore in the quarter ended December 2025 as against Rs 185.65 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales206.44185.65 11 OPM %34.9235.52 - PBDT74.2067.54 10 PBT67.3862.58 8 NP49.6846.78 6 Powered by Capital Market - Live

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Net profit of Supriya Lifescience rose 9.27% to Rs 50.43 crore in the quarter ended September 2025 as against Rs 46.15 crore during the previous quarter ended September 2024. Sales rose 20.31% to Rs 199.83 crore in the quarter ended September 2025 as against Rs 166.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales199.83166.10 20 OPM %36.3638.96 - PBDT74.9666.81 12 PBT68.3262.07 10 NP50.4346.15 9 Powered by Capital Market - Live